Abstract
Whilst there is a small literature on the cardiovascular toxicity of opiates, there is no detailed antemortem data on non-cardiovascular patient populations. A cross-sectional and longitudinal naturalistic observational study was performed comparing methadone (N = 71)-, buprenorphine (N = 593)-, naltrexone (N = 23)-treated patients with controls (N = 576) on indices of arterial stiffness and vascular age by Pulse Wave Analysis in primary care, 2006–2011. Controls were younger 29.96 ± 0.45 (mean ± SEM) vs. 34.00 ± 0.34–39.22 ± 1.11 years (all P < 0.005) and had fewer smokers (15.9 % vs. 86.9 %–92.96 %, all P < 0.0001). The sex ratio was similar (69.6 vs. 67.7 % male, P = 0.46). These baseline differences were controlled for by multiple regression. Linear regression of vascular age, central augmentation pressure, central augmentation index and other measures against chronologic age showed significant protective effects by treatment group against the treatment standard of methadone, in both sexes in additive and interactive models (all P < 0.02). Interactive terms in treatment type remained significant including all conventional risk factors accounting for differing opiate exposures. The principal findings from multiple regression were confirmed in the time series analysis up to 5 years by repeated measures nonlinear regression. These studies show that the deleterious impact of chronic opiate pharmacotherapy on vascular age and arterial stiffness varies significantly by treatment type.
Similar content being viewed by others
References
Centers for Disease Control, Prevention (CDC). (2011). Vital signs: overdoses of prescription opioid pain relievers—United States, 1999–2008. Morbidity and Mortality Weekly Report, 60, 1487–1492.
Jamison, R. N., Serraillier, J., & Michna, E. (2011). Assessment and treatment of abuse risk in opioid prescribing for chronic pain. Pain Research and Treatment, 2011, 941808.
Degenhardt, L., Randall, D., Hall, W., Law, M., Butler, T., & Burns, L. (2009). Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: Risk factors and lives saved. Drug and Alcohol Dependence, 105(1–2), 9–15.
Kimber, J., Copeland, L., Hickman, M., Macleod, J., McKenzie, J., De Angelis, D., et al. (2010). Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. BMJ (Clinical research ed), 341, c3172.
Brunton, L. L., Lazo, J. S., & Parker, K. L. (Eds.). (2006). Goodman and Gilman’s the pharmacologic basis of therapeutics (11th ed., Vol. 1). New York: McGraw Hill.
McLaughlin, P. J., Zagon, I. S., & White, W. J. (1978). Perinatal methadone exposure in rats. Effects on body and organ development. Biology of the Neonate, 34(1–2), 48–54.
Cheng, F., McLaughlin, P. J., Verderame, M. F., & Zagon, I. S. (2009). The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation. Molecular Biology of the Cell, 20(1), 319–327.
Helgadottir, A., Thorleifsson, G., Manolescu, A., Gretarsdottir, S., Blondal, T., Jonasdottir, A., et al. (2007). A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science, 316(5830), 1491–1493.
McPherson, R., Pertsemlidis, A., Kavaslar, N., Stewart, A., Roberts, R., Cox, D. R., et al. (2007). A common allele on chromosome 9 associated with coronary heart disease. Science, 316(5830), 1488–1491.
Feero, W. G., Guttmacher, A. E., & McCarthy, M. I. (2010). Genomics, Type 2 diabetes, and obesity. New England Journal of Medicine, 363(24), 2339–2350.
O’Donnell, C. J., & Nabel, E. G. (2011). Genomics of cardiovascular disease. New England Journal of Medicine, 365(22), 2098–2109.
Pasmant, E., Sabbagh, A., Vidaud, M., & Bieche, I. (2010). ANRIL, a long, noncoding RNA, is an unexpected major hotspot in GWAS. The FASEB Journal, 25(2), 444–448.
Holdt, L. M., Beutner, F., Scholz, M., Gielen, S., Gabel, G., Bergert, H., et al. (2010). ANRIL expression is associated with atherosclerosis risk at chromosome 9p21. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(3), 620–627.
Khademi, H., Malekzadeh, R., Pourshams, A., Jafari, E., Salahi, R., Semnani, S., et al. (2012). Opium use and mortality in Golestan Cohort Study: prospective cohort study of 50, 000 adults in Iran. BMJ (Clinical research ed), 344, e2502.
Darke, S., Kaye, S., & Duflou, J. (2006). Systemic disease among cases of fatal opioid toxicity. Addiction, 101(9), 1299–1305.
Sadeghian, S., Darvish, S., Davoodi, G., Salarifar, M., Mahmoodian, M., Fallah, N., et al. (2007). The association of opium with coronary artery disease. European Journal of Cardiovascular Prevention & Rehabilitation, 14(5), 715–717.
Sadeghian, S., Dowlatshahi, S., Karimi, A., & Tazik, M. (2011). Epidemiology of opium use in 4398 patients admitted for coronary artery bypass graft in Tehran Heart Center. The Journal of Cardiovascular Surgery (Torino), 52(1), 140–141.
Claude Bernard, M. (1877). Lecons Sur Le Diabete et la Glycogenese Animale (Vol. 1). Paris: Cours de Medecine.
Rosen, D., Smith, M. L., & Reynolds, C. F., 3rd. (2008). The prevalence of mental and physical health disorders among older methadone patients. American Journal of Geriatric Psychiatry, 16(6), 488–497.
Cooper, O. B., Brown, T. T., & Dobs, A. S. (2003). Opiate drug use: a potential contributor to the endocrine and metabolic complications in human immunodeficiency virus disease. Clinical Infectious Diseases, 37(Suppl 2), S132–S136.
Kolarzyk, E., Pach, D., Wojtowicz, B., Szpanowska-Wohn, A., & Szurkowska, M. (2005). Nutritional status of the opiate dependent persons after 4 years of methadone maintenance treatment. Przeglad Lekarski, 62(6), 373–377.
Darke, S., Duflou, J., & Torok, M. (2010). The comparative toxicology and major organ pathology of fatal methadone and heroin toxicity cases. Drug and Alcohol Dependence, 106(1), 1–6.
Reece, A. S. (2009). Dental health in addiction. Australian Dental Journal, 54(2), 185–186.
Friedewald, V. E., Kornman, K. S., Beck, J. D., Genco, R., Goldfine, A., Libby, P., et al. (2009). The American Journal of Cardiology and Journal of Periodontology editors’ consensus: periodontitis and atherosclerotic cardiovascular disease. Journal of Periodontology, 80(7), 1021–1032.
Zagon, I. S., Verderame, M. F., & McLaughlin, P. J. (2002). The biology of the opioid growth factor receptor (OGFr). Brain Research Reviews, 38(3), 351–376.
Nichols, W. W., Denardo, S. J., Wilkinson, I. B., McEniery, C. M., Cockcroft, J., & O’Rourke, M. F. (2008). Effects of arterial stiffness, pulse wave velocity, and wave reflections on the central aortic pressure waveform. The Journal of Clinical Hypertension (Greenwich), 10(4), 295–303.
Laurent, S., Boutouyrie, P., Asmar, R., Gautier, I., Laloux, B., Guize, L., et al. (2001). Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension, 37(5), 1236–1241.
AtCor Medical Corporation. (2006). SphygmoCor pulse wave analysis system model SCOR-Px. PP1–63 (1st ed., Vol. 1). Sydney: Atcor Medical.
Reece, A. S. (2007). Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program. Substance Abuse Treatment, Prevention, and Policy, 2, 35–49.
Hulse, G., White, J., & Cape, G. (Eds.). (2002). Management of drug and alcohol problems (Vol. 1). Sydney: Oxford University Press.
Kienbaum, P., Thurauf, N., Michel, M. C., Scherbaum, N., Gastpar, M., & Peters, J. (1998). Profound increase in epinephrine concentration in plasma and cardiovascular stimulation after mu-opioid receptor blockade in opioid-addicted patients during barbiturate-induced anesthesia for acute detoxification. Anesthesiology, 88(5), 1154–1161.
Chien, K. R., & Karsenty, G. (2005). Longevity and lineages: toward the integrative biology of degenerative diseases in heart, muscle, and bone. Cell, 120(4), 533–544.
Visel, A., Zhu, Y., May, D., Afzal, V., Gong, E., Attanasio, C., et al. (2010). Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature, 464(7287), 409–412.
Harismendy, O., Notani, D., Song, X., Rahim, N. G., Tanasa, B., Heintzman, N., et al. (2011). 9p21 DNA variants associated with coronary artery disease impair interferon-gamma signalling response. Nature, 470(7333), 264–268.
Hutchinson, M. R., Zhang, Y., Shridhar, M., Evans, J. H., Buchanan, M. M., Zhao, T. X., et al. (2010). Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain, Behavior, and Immunity, 24(1), 83–95.
Yin, D., Woodruff, M., Zhang, Y., Whaley, S., Miao, J., Ferslew, K., et al. (2006). Morphine promotes Jurkat cell apoptosis through pro-apoptotic FADD/P53 and anti-apoptotic PI3 K/Akt/NF-kappaB pathways. Journal of Neuroimmunology, 174(1–2), 101–107.
Grzanna R., & Brown R. M. (1993). NIDA research monograph 125: Activation of intermediate early genes by drugs of abuse. In: National Institutes of Drug Abuse (Ed.) (Vol. 125, pp. 1–220). Bethesda, Maryland: NIH.
Varela, E., & Blasco, M. A. (2010). 2009 Nobel Prize in physiology or medicine: telomeres and telomerase. Oncogene, 29(11), 1561–1565.
Martinez, P., & Blasco, M. A. (2011). Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nature Reviews Cancer, 11(3), 161–176.
Martinez, P., Thanasoula, M., Carlos, A. R., Gomez-Lopez, G., Tejera, A. M., Schoeftner, S., et al. (2010). Mammalian Rap1 controls telomere function and gene expression through binding to telomeric and extratelomeric sites. Nature Cell Biology, 12(8), 768–780.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Reece, A.S., Hulse, G.K. Impact of Opioid Pharmacotherapy on Arterial Stiffness and Vascular Ageing: Cross-Sectional and Longitudinal Studies. Cardiovasc Toxicol 13, 254–266 (2013). https://doi.org/10.1007/s12012-013-9204-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12012-013-9204-4